Comparison of the systemic and intratumoral effects of tamoxifen and the aromatase inhibitor vorozole in postmenopausal patients with primary breast cancer

Journal of Clinical Oncology

Volumn 20, Issue 4, 2002, Pages 1026-1035

  Harper Wynne, Catherine L ^a   Sacks, Nigel P M ^a   Shenton, Karyn ^a   MacNeill, Fiona A ^a   Sauven, Paul ^a   Laidlaw, Ian J ^a   Rayter, Zen ^a   Miall, Stephanie ^a   Howes, Angela ^a   Salter, Janine ^a   Hills, Margaret J ^a   Lowe, Frances M ^a   A'Hern, Roger ^a   Nasiri, Nazar ^a   Doody, Debbie ^a   Iqbal, Jhangir ^a   Dowsett, Mitchell ^a  

^a ROYAL MARSDEN HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AROMATASE INHIBITOR; ESTRADIOL; ESTROGEN DERIVATIVE; ESTROGEN RECEPTOR; FOLLITROPIN; KI 67 ANTIGEN; LIPID; LUTEINIZING HORMONE; PROGESTERONE RECEPTOR; SEX HORMONE BINDING GLOBULIN; SOMATOMEDIN; TAMOXIFEN; VOROZOLE;

ADULT; AGED; APOPTOSIS; ARTICLE; BONE METABOLISM; BREAST CANCER; CANCER CHEMOTHERAPY; CLINICAL EXAMINATION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORRELATION ANALYSIS; DRUG INDUCED DISEASE; DRUG RESPONSE; ESTRADIOL BLOOD LEVEL; ESTROGEN BLOOD LEVEL; FEMALE; FOLLITROPIN BLOOD LEVEL; HUMAN; LIPID METABOLISM; LUTEINIZING HORMONE BLOOD LEVEL; MAJOR CLINICAL STUDY; POSTMENOPAUSE; PREOPERATIVE TREATMENT; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; STATISTICAL ANALYSIS; TUMOR VOLUME;

ADMINISTRATION, ORAL; AGED; ANTINEOPLASTIC AGENTS, HORMONAL; BREAST NEOPLASMS; ENZYME INHIBITORS; FEMALE; FOLLICLE STIMULATING HORMONE; HUMANS; KI-67 ANTIGEN; LUTEINIZING HORMONE; MIDDLE AGED; POSTMENOPAUSE; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; TAMOXIFEN; TRIAZOLES; TUMOR MARKERS, BIOLOGICAL;

EID: 0037083289     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.20.4.1026     Document Type: Article

References (48)

1. Aromatase inhibitors come of age
2. Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy: 133 Randomised trials involving 31,000 recurrences and 24,000 deaths among 75,000 women
3. Polychemotherapy for early breast cancer: An overview of the randomised trials
4. Effect of preoperative chemotherapy on the outcome of women with operable breast cancer
5. Lessons from the use of aromatase inhibitors in the neoadjuvant setting
6. Letrozole is more effective neoadjuvant endocrine therapy than tamoxifen for ErbB-1- and/or ErbB-2-positive, estrogen receptor positive pirmary breast cancer: Evidence from a phase III randomized trial
7. Aromatase inhibitors in the treatment and prevention of breast cancer
8. Recent advances in endocrine therapy of breast cancer
9. In vivo measurement of aromatase inhibition by letrozole (CGS 20267) in postmenopausal patients with breast cancer
10. Inhibition of the in vivo conversion of androstenedione to estrone by the aromatase inhibitor vorozole in healthy postmenopausal women
11. Anastrozole is superior to tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women: Results of a North American multicenter randomized trial
12. Superior efficacy of letrozole versus tamoxifen as first-line therapy for postmenopausal women with advanced breast cancer: Results of a phase 111 study of the International Letrozole Breast Cancer Group
13. Tamoxifen for early breast cancer: An overview of the randomised trials
14. Induction of apoptosis by tamoxifen and ICI 182780 in primary breast cancer
15. Idoxifene antagonizes estradiol-dependent MCF-7 breast cancer xenograft growth through sustained induction of apoptosis
16. Programmed cell death during regression of the MCF-7 human breast cancer following estrogen ablation
17. Time-related effects of estrogen withdrawal on proliferation- and cell death-related events in MCF-7 xenografts
18. Effect of tamoxifen on Ki67 labelling index in human breast tumours and its relationship to oestrogen and progesterone receptor status
19. Effects of short-term pre-operative tamoxifen on steroid receptor and Ki-67 expression in primary breast cancer: An immunocytochemical study
20. Changes in hormone receptors and proliferation markers in tamoxifen treated breast cancer patients and the relationship with response
21. Steroid hormone receptors and carcinoma of the breast
22. Insulin-like growth factors in human breast cancer
23. Investigation of a new pure antiestrogen (ICI 182780) in women with primary breast cancer
24. Comparison of in situ methods to assess DNA cleavage in apoptotic cells in patients with breast cancer
25. Use of the aromatase inhibitor 4-hydroxyandrostenedione in postmenopausal breast cancer: Optimization of therapeutic dose and route
26. Randomized phase III trial comparing the new potent and selective third-generation aromatase inhibitor vorozole with megestrol acetate in postmenopausal advanced breast cancer patients: The North American Vorozole Study Group
27. Serum elimination half-life of tamoxifen and its metabolites in patients with advanced breast cancer
28. Pharmacokinetics of vorozole in breast cancer patients
29. Comparison of MIBI proliferation index and s-phase fraction in human breast carcinomas
30. Mechanisms of hormone response: A role for apoptosis
31. Integrated control of cell proliferation and cell death by the c-myc oncogene
32. Insulin-like growth factor-1 inhibits cell death induced by anticancer drugs in the MCF-7 cells: Involvement of growth factors in drug resistance
33. Influence of tamoxifen, aminoglutethimide and goserelin on human plasma IGF-I levels in breast cancer patients
34. The aromatase inhibitor letrozole in advanced breast cancer: Effects on serum insulin-like growth factor (IGF)-I and IGF-binding protein-3 levels
35. Effect of two 4-hydroxyandrostenedione doses on serum insulin-like growth factor I levels in advanced breast cancer
36. Effects of treatment with megestrol acetate, aminoglutethimide, or formestane on insulin-like growth factor (IGF) I and II, IGF-binding proteins (IGFBPs), and IGFBP-3 protease status in patients with advanced breast cancer
37. Prediction of clinical outcome from primary tamoxifen by expression of biologic markers in breast cancer patients
38. Endocrine therapy for advanced carcinoma of the breast: Relationship between the effect of tamoxifen upon concentrations of progesterone receptor and subsequent response to treatment
39. Influence of tamoxifen on sex hormones, gonadotrophins and sex hormone binding globulin in postmenopausal breast cancer patients
40. Clinical and endocrine effects of the oral aromatase inhibitor vorozole in postmenopausal patients with advanced breast cancer
41. Phase II study of vorozole (R83842), a new aromatase inhibitor, in postmenopausal women with advanced breast cancer in progression on tamoxifen
42. Effects of tamoxifen on cardiovascular risk factors in postmenopausal women after 5 years of treatment
43. Endocrine and clinical effects of exemestane (PNU 155971), a novel steroidal aromatase inhibitor, in postmenopausal breast cancer patients: A phase I study
44. Effect of the potent aromatase inhibitor fadrozole hydrochloride (CGS 16949A) in postmenopausal women with breast carcinoma
45. Effect of tamoxifen on bone mineral density measured by dual-energy x-ray absorptiometry in healthy premenopausal and postmenopausal women
46. Serum CrossLaps for monitoring the response in individuals undergoing antiresorptive therapy
47. Aromatase inhibitors and their use in the adjuvant setting
48. Aromatase inhibitors and their future role in post-menopausal women with early breast cancer